+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID07722611

Evaluating Bomedemstat Versus Standard Treatments for Polycythemia Vera in Participants Unresponsive or Intolerant to Hydroxyurea

Led by Merck Sharp & Dohme LLC · Updated on 2026-10-21

380

Participants Needed

2

Research Sites

22 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are exploring new treatments for polycythemia vera PV, a condition where the body produces too many red blood cells. This study evaluates a medicine called bomedemstat MK-3543 compared to two standard treatments, ropeginterferon alfa-2b and ruxolitinib, in people with PV who have not responded well or are intolerant to hydroxyurea. The goal is to see if bomedemstat helps more participants reach healthy blood counts and avoid major health problems related to PV. Participants will be randomly assigned to receive either bomedemstat daily for up to about 52 weeks, with doses adjusted to meet blood count targets, or one of the standard treatments ropeginterferon alfa-2b or ruxolitinib, given according to approved guidelines for about the same duration. Those who continue treatment beyond 52 weeks may keep receiving their assigned study medication. During the study, participants will be monitored regularly with evaluations to measure blood cell counts and health status up to week 52. Researchers will track responses such as clinicohematologic response rates, adverse events, discontinuations, blood transfusions, disease progression, and symptom changes. The study also observes longer-term outcomes and safety throughout the treatment period.

CONDITIONS

Brief Title

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).

Research Team

T

Toll Free Number

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here